menu
    • menu

    Company profile for Crucell

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011 and as of October 2014 Crucell is changing its identity into Janssen. For Janssen, the acquisition of Crucell has provided a firm foothold in the increasingly important field of disease prevention. Ultimately, this should mean that many more people around the world can live longer, healthier lives—and we are passionately committed to ma...
    Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011 and as of October 2014 Crucell is changing its identity into Janssen. For Janssen, the acquisition of Crucell has provided a firm foothold in the increasingly important field of disease prevention. Ultimately, this should mean that many more people around the world can live longer, healthier lives—and we are passionately committed to making that happen. Innovation is the driving force behind our strong vaccine research and development pipeline. We have promising candidates in preclinical and clinical development, supported by a range of patented technologies such as our PER.C6® human cell-line technology, which will enable faster and more cost-effective production of our future vaccines and biologicals. Clean water, immunization, and antiviral and antibacterial medicines are considered the top three interventions driving improvements in public health. And with infectious diseases on the rise worldwide, developing innovative products to prevent or treat them is becoming increasingly urgent.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CrucellCanada Flag
    Country
    Country
    Canada
    Address
    Address
    19 Green Belt Drive Toronto, ON M3C 1L9
    Telephone
    Telephone
    +1-416-382-4986
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://crucell.com/, http://www.crucellvaccinescanada.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Human Vaccines Project & Boehringer Partner to Develop of Cancer Vaccines
    Human Vaccines Project & Boehringer Partner to Develop of Cancer Vaccines

    21 Nov 2016

    // DRUG DEVELOPMENT

    http://www.drug-dev.com/Main/Current-News/The-Human-Vaccines-Project-Boehringer-Ingelheim-Pa-1766.aspx

    DRUG DEVELOPMENT
    21 Nov 2016
    Share Share
    ProQR tank after slow enrollment pushes back readout from cystic fibrosis trial
    ProQR tank after slow enrollment pushes back readout from cystic fibrosis trial

    24 Nov 2015

    // Nick Paul Taylor FIERCE BIOTECH

    http://www.fiercebiotech.com/story/proqr-tanks-after-slow-enrollment-pushes-back-readout-cystic-fibrosis-trial/2015-11-24

    Nick Paul Taylor FIERCE BIOTECH
    24 Nov 2015
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search